Telaprevir Prospects Improve With Positive Findings In Twice-daily Dosing
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex reports trial data on hepatitis C candidate show twice-daily dosing efficacy, increased sustained virologic response.